The European Union prohibits six beauty product ingredients that remain fully legal on United States shelves, according to a review published by The Week. That single digit — six — understates the wider regulatory divergence it represents for anyone formulating, importing, or retailing cosmetics across both markets.

The count highlights a structural split that has widened over decades. The EU regulates cosmetics through a pre-market safety system: ingredients and substances of concern are restricted or prohibited centrally, and the list of banned substances runs well over a thousand entries. The United States, by contrast, historically operated a reactive regime in which the Food and Drug Administration could act only after evidence of harm accumulated in the marketplace. The Modernization of Cosmetics Regulation Act of 2022, or MoCRA, tightened US oversight — mandatory facility registration, adverse-event reporting, safety substantiation — but it did not import the EU's prohibition list.

For formulators, the practical consequence is straightforward. A brand sold in both regions either maintains two versions of the same product or reformulates to the stricter standard for all markets. Most multinationals choose the second path, which is why EU rules effectively set a de facto global benchmark. Smaller US-only brands, however, can still use the six substances at issue without violating federal law — a point consumers increasingly notice, especially as retailers begin applying their own restricted-substance lists that go beyond FDA requirements.

For compliance teams, the divergence creates classification work rather than drama. Each ingredient on the EU's prohibited list must be checked against existing SKUs, supplier documentation, and Certificate of Analysis data before any EU shipment. If a US-formulated product contains one of the six banned substances, the EU market is closed until the formula changes and the updated Product Information File reflects it. The cost is measured in reformulation cycles, stability retesting, and relabeling — not fines, because non-compliant product simply cannot be placed on the EU market at all.

The gap also carries procurement implications. Buyers sourcing finished goods from US manufacturers for European distribution need contractual guarantees that formulas meet EU requirements, not just FDA ones. The reverse flow — EU-made products entering the US — is rarely a problem, since the stricter standard clears both.

Consumer pressure is narrowing the practical divide faster than legislation is. Media coverage of the kind The Week has published tends to frame the six ingredients as evidence of lax US oversight, and that framing influences purchasing behavior even where the regulatory status is unchanged. Brands marketing "EU-compliant" formulations as a selling point are already exploiting the perception.

Whether Congress closes the gap is a separate question. MoCRA's implementation timeline runs through ongoing FDA rulemaking on facility registration, adverse events, and safety substantiation, but no proposal currently on the table would harmonize US ingredient prohibitions with the EU's annexes. For now, the six-ingredient gap stands as a working fact of the industry.

The next data points to watch: FDA's remaining MoCRA rulemakings and any states-level action — California's approach to cosmetic safety has already shown that state legislatures will move where federal rules do not.